THE SMARTER E EUROPE 2022: INNOVATIVE SOLUTIONS FOR THE ENERGY TRANSITION AND SECURITY OF SUPPLY
30.3.2022 11:05:00 EEST | Business Wire | Press release
Independence from fossil fuels is key for climate protection – and is of relevance for security policy in light of Russia’s war in Ukraine. Europe must make enormous strides towards renewable energies in order to achieve climate targets and ensure security of supply. At The smarter E Europe – Europe's largest platform for the energy industry – 1,450 exhibitors will present innovative products and solutions to 50,000 trade visitors over an exhibition area of 132,000 m2 from May 11 to 13 in Munich.
Rising electricity and gas prices and dependence on Russian gas are giving the energy transition a tailwind. The transition is urgently needed, and possible: photovoltaics (PV) have been successful for two decades, the energy storage industry has been gaining traction for ten years, and electromobility and charging infrastructure are booming. The solutions for an independent energy supply are ready - now it is time to deploy them sustainably. Renewable energy, decentralization, digitalization, sector coupling, smart and networked energy systems as well as smart charging systems and e-mobility are the focus of The smarter E Europe 2022. Another key topic is green hydrogen. At the exhibition, the “Green Hydrogen Forum & Expo” will provide important impetus for bringing hydrogen, fuel cells, electrolysis and power-to-gas technology to the markets at an accelerated pace.
Focus on energy and mobility transition
The smarter E Europe includes four energy exhibitions: Intersolar Europe, ees Europe, Power2Drive Europe and EM-Power Europe. At Intersolar Europe, companies will present cell concepts and modules as well as inverters and solutions for building-integrated PV, agri-PV (simultaneous land use for agriculture and electricity production using PV systems) and floating PV systems. However, solar power alone does not make an energy transition; rather, what is needed is integrated solutions for a full supply of renewable energy 24/7 and across all seasons. The focus of ees Europe 2022 will therefore be on storage technologies, and in particular battery storage and green hydrogen.
Renewable energy and interconnected energy systems are closely linked to the goal of climate neutrality and the need to reassess security of supply. EM-Power Europe will therefore present smart grid solutions, smart buildings and neighborhoods, and digital business models for municipal utilities and energy providers. Power2Drive Europe will demonstrate the interconnectedness of new energies and mobility and explore everything related to the mobility of the future. This includes in particular intelligent charging solutions, vehicle-to-grid technologies, solar charging infrastructure and e-vehicles.
On May 10 – the day before the exhibition opens – visitors to the accompanying specialist conferences will discover all facets of the new energy world. In the evening, the industry innovation drivers will be honored with the Intersolar AWARD, the ees AWARD and The smarter E AWARD. Exhibition forums and workshops will bring visitors together with key industry representatives.
The smarter E Europe, which encompasses the four individual exhibitions will take place from May 11–13, 2022, at Messe München.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005519/en/
Contact information
Contact:
Solar Promotion GmbH | PO Box 100 170 | 75101 Pforzheim
Horst Dufner | Tel.: +49 7231 58598-0 | Fax: +49 7231 58598-28
dufner@solarpromotion.de
Press contact:
fischerAppelt, relations | Otl-Aicher-Str. 64 | 80807 Munich
Felizia Rein| Tel. +49 89 74 74 66 40
felizia.rein@fischerappelt.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release
Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom